■在诊断和治疗嗜麦芽窄食单胞菌菌血症方面存在许多困难。在这项研究中,我们旨在评估"真"和"假阳性菌血症",并评估死亡危险因素和不同治疗方案的影响.
■通过两阶段分析评估嗜麦芽嗜血杆菌阳性的住院成年患者。首先,评估血培养的临床意义,将患者分为“真菌血症”和“假阳性菌血症”组。然后,排除误报,我们在进行单因素和多因素分析的真菌血症病例中分析了抗菌方案和与28日死亡率相关的因素.
■该研究包括138例嗜麦芽嗜血杆菌菌血症患者中的127例。51.2%的患者发现了真正的菌血症,48.8%的患者发现了假阳性菌血症。在真正的菌血症组中,低血压,医院菌血症,伴随感染,菌血症的来源,两组阳性血培养物,28天死亡率更为常见。在真正的菌血症病例中,28天死亡率为50.7%。在多变量分析中,年龄和实体瘤是28日死亡率的独立预测因子.早期有效的抗菌治疗和不同的抗菌方案,包括甲氧苄啶-磺胺甲恶唑(SXT),氟喹诺酮类药物(FQs),和替加环素(TGC),对生存率没有任何显著影响。
■嗜麦芽嗜血杆菌菌血症患者应首先评估其临床意义。临床发现,多个阳性血培养组的存在和菌血症的主要来源是有用的参数,同时区分真菌血症和假阳性菌血症.在死亡率方面,应仔细跟踪高龄和实体瘤的患者。抗菌方案,包括SXT,FQs,或TGC,考虑到抗菌药物耐药性和不良反应或毒性,嗜麦芽嗜血杆菌菌血症患者可以首选。
UNASSIGNED: There are many difficulties in diagnosing and treating Stenotrophomonas maltophilia bacteremia. In this study, we aimed to evaluate \"true\" and \"false-positive bacteremia\" and assess mortality risk factors and the impact of different treatment regimens.
UNASSIGNED: Hospitalized adult patients with S. maltophilia-positive blood cultures were assessed by a two-stage analysis. First, the clinical significance of blood cultures was assessed, and patients were divided into \"true\" and \"false-positive bacteremia\" groups. Then, excluding false positives, we analyzed the antimicrobial regimens and the factors associated with 28-day mortality in true bacteremia cases performing univariate and multivariate analyses.
UNASSIGNED: The study included 127 out of 138 patients with S. maltophilia bacteremia. True bacteremia was identified in 51.2% and false-positive bacteremia in 48.8% of patients. In the true bacteremia group, hypotension, nosocomial bacteremia, concomitant infections, a source of bacteremia, two positive blood culture sets, and 28-day mortality were more common. The 28-day mortality was 50.7% among true bacteremia cases. In multivariate analysis, age and solid tumor were the independent predictors of 28-day mortality. Early effective antimicrobial therapy and different antimicrobial regimens, including trimethoprim-sulfamethoxazole (SXT), fluoroquinolones (FQs), and tigecycline (TGC), did not have any significant impact on survival.
UNASSIGNED: Patients with S. maltophilia bacteremia should first be assessed regarding clinical significance. Clinical findings, the presence of multiple positive blood culture sets and the primary sources of bacteremia are useful parameters while discriminating true from false-positive bacteremia. Patients with advanced age and solid tumors should be followed carefully in terms of mortality. Antimicrobial regimens, including SXT, FQs, or TGC, can be preferred in patients with S. maltophilia bacteremia considering antimicrobial resistance and adverse effects or toxicity.